Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis*

Annemarie J. van der Slot‡, Anne-Marie Zuurmond‡, Alfonso F. J. Barodoës, Cisca Wijmenga§, Hans E. H. Pruisj§§, David O. Sillence**, Jürgen Brinckmann**, David J. Abraham‡‡, Carol M. Black‡‡, Nicole Verzijl‡, Jeroen DeGroot‡, Roeland Hanemaaijer‡, Johan M. TeKoppele‡, Tom W. J. Huizinga§§, and Ruud A. Bank†††

From ‡TNV Prevention and Health, Division Biomedical Research, Department Tissue Repair, P. O. Box 2215, 2301 CE Leiden, The Netherlands, the §Department of Medical Genetics, University Medical Center Utrecht, Leudalduinlaan 6, 3584 EA Utrecht, The Netherlands, the ¶Department of Pediatric Orthopedics, University Medical Center Utrecht, P. O. Box 19009, 3501 CA Utrecht, The Netherlands, the ‡Department of Pediatrics and Child Health, The Children’s Hospital at Westmead, New South Wales 2145, Australia, the ¶¶Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, 23555 Lübeck, Germany, the §§Centre for Rheumatology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom, and the ¶¶¶Department of Rheumatology, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands

The hallmark of fibrotic processes is an excessive accumulation of collagen. The deposited collagen shows an increase in pyridinoline cross-links, which are derived from hydroxylated lysine residues within the telopeptides. This change in cross-linking is related to irreversible accumulation of collagen in fibrotic tissues. The increase in pyridinoline cross-links is likely to be the result of increased activity of the enzyme responsible for the hydroxylation of the telopeptides (telopeptide lysyl hydroxylase, or TLH). Although the existence of TLH has been postulated, the gene encoding TLH has not been identified. By analyzing the genetic defect of Bruck syndrome, which is characterized by a pyridinoline deficiency in bone collagen, we found two missense mutations in exon 17 of PLOD2, thereby identifying PLOD2 as a putative TLH gene. Subsequently, we investigated fibroblasts derived from fibrotic skin of systemic sclerosis (SSc) patients and found that PLOD2 mRNA is highly increased indeed. Furthermore, increased pyridinoline cross-link levels were found in the matrix deposited by Scs fibroblasts, demonstrating a clear link between mRNA levels of the putative TLH gene (PLOD2) and the hydroxylation of lysine residues within the telopeptides. These data underscore the significance of PLOD2 in fibrotic processes.

The biosynthesis of collagen molecules involves several intracellular post-translational modifications followed by extracellular and extracellular aggregation of the collagen molecules into fibrils, which are subsequently stabilized by intermolecular cross-links (1, 2). Two related routes are responsible for the formation of these collagen cross-links, namely the allysine route, in which a lysine residue in the telopeptide is converted into the aldehyde hydroxyallysine. Subsequently, the allysine or the hydroxyallysine reacts with a Lys residue in the triple helix to form dh-, tri-, or tetrafunctional cross-links (3–6). The mature cross-links hydroxyallysine-derived or lysylpyridinoline or lysylpyridinoline are formed via the hydroxyallysine route and occur in a variety of connective tissues such as bone, tendon, ligaments, and cartilage (7). In contrast, collagen in the skin is mainly cross-linked via the allysine route. Interestingly, in fibrotic skin (lipodermatosclerosis, keloid) and organ fibrosis (lung, liver), which is characterized by an excessive accumulation of collagen, an increase in cross-links derived from the hydroxyallysine route is found (8–15). It has been shown that the amount of hydroxyallysine-derived cross-links is related to the irreversible accumulation of collagen in fibrotic tissues, indicating that collagen containing hydroxyallysine-derived cross-links is more difficult to degrade than collagen containing allysine-derived cross-links (10–12, 14, 15). Inhibition of the formation of hydroxyallysine-derived cross-links in fibrosis is therefore likely to result in the formation of collagen that is easier to degrade, thereby preventing the unwanted collagen accumulation.

The increase in hydroxyallysine-derived cross-links in fibrosis is the result of an overhydroxylation of lysine residues within the collagen telopeptides. The enzyme catalyzing the conversion of Lys into Hyl is lysyl hydroxylase (EC 1.14.11.4) (16–18). The lysyl hydroxylase family consists of lysyl hydroxylase 1 (LH1), LH2, and LH3 encoded by procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1), PLOD2, and PLOD3, respectively (16, 19–21). Alternative RNA splicing has been described for PLOD2 only, resulting in the splice variants LH2a and LH2b (LH2b contains an extra exon; Ref. 22). The Ehlers-Danlos syndrome type VI is characterized by mutations in PLOD1. Collagen of these patients shows an absence of hydroxylated lysine residues within the triple helix in combination with normal levels of hydroxylated lysine residues within the telopeptides. Therefore, it can be concluded that LH1 catalyzes the conversion of triple helical lysine residues into hydroxylysines (23, 24). The substrate specificity of LH2

* This study was supported by Netherlands Organization for Scientific Research (NWO) Grant 902-27-222, Dutch Arthritis Association Grant 99-2-201, the Arthritis Research Campaign (United Kingdom), the Raynauds and Scleroderma Association, and Deutsche Forschungsgemeinschaft Grant DFG Br1146/3-1. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

††† To whom correspondence should be addressed. Tel.: 31-715-18-1503; Fax: 31-715-18-1901; E-mail: RA.Bank@pg.tno.nl.

1 The abbreviations used are: LH, lysyl hydroxylase; BS, Bruck syndrome; COL1A2, collagen type 1 α2 chain; LOX, lysyl oxidase; PLOD, procollagen-lysine, 2-oxoglutarate 5-dioxygenase; SSc, systemic sclerosis; TLH, telopeptide lysyl hydroxylase.
and LH3 has not yet been elucidated, and to date no disease has been associated with defects in LH2 or LH3.

Bruck syndrome (BS; Online Mendelian Inheritance in Man (OMIM) accession number 259450), an autosomal recessive disease, is characterized by osteoporosis, joint contractures at birth, fragile bones, and short stature (25–28). Biochemical analysis of the bone of BS patients revealed an underhydroxylation of lysine residues in the telopeptides of collagen type I, whereas hydroxylation of lysine residues in the triple helix is normal (29). Together, the Ehlers-Danlos syndrome type VI and the Bruck syndrome imply that a lysyl hydroxylase must exist that specifically hydroxylates the telopeptides and that the activity of such a telopeptide lysyl hydroxylase (TLH) is shown that the gene defect in two BS families is a mutation in PLOD2, showing that PLOD2 encodes TLH. The importance of TLH in fibrotic processes is demonstrated by the highly increased expression of TLH in fibroblasts cultured from the fibrotic skin of systemic sclerosis (SSc) patients. Furthermore, higher levels of pyridinoline cross-links were found in the extracellular matrix deposited by the SSc fibroblasts, which contains of both genes are identical. Analysis of clones RP11-758H14 and RP11-274H2 showed identical exon/intron boundaries for PLOD2. In addition, PLOD2 shows an extra exon (22), designated exon 13A, which is not found in PLOD1 or PLOD3. To determine DNA sequence variations in exons and exon/intron boundaries of PLOD2, primer pairs were designed to amplify the exons, including the exon/intron boundaries; in addition, a part of the promoter region was amplified (Table I). PCR was carried out on genomic DNA from Bruck syndrome patients, unaffected parents, and a pooled healthy population. Purified PCR products served as templates for cycle sequencing using the ABI PRISM® Big Dye termination cycle sequencing ready reaction kit (Applied Biosystems) and were analyzed on the ABI PRISM® 310 sequencer (Applied Biosystems). Fibroblast Cultures—Primary fibroblast cultures from skin biopsies of six patients with diffuse cutaneous SSc were established by routine methods. Control cultures were obtained from biopsies taken from 10 healthy controls. Cells were grown in minimal essential medium alpha containing 1% fetal calf serum (FCS), 100 units/ml penicillin, and 100 units/ml streptomycin until they reached subconfluence. Cells were detached using 0.5 ml of 0.05% trypsin/0.02% EDTA per 25 cm² and used for total RNA isolation.

**Experimental Procedures**

**Patients**—In this study, three families with children diagnosed as Bruck syndrome patients were investigated. Two unrelated Kurdish families (families FH and PM), both consanguineous, were described earlier (cases 1, 2, and 3, and 7 and 8, respectively) (26); the third family (family DR) has not yet been described. This Australian family, where the parents are not consanguineous, had two affected boys deceased prenatally, one affected girl deceased at 2 years, and one surviving unaffected 9-year-old girl. All these BS patients show decreased amounts of pyridinoline cross-links in bone.

**Genotyping**—Blood samples of the three families were collected, and genomic DNA was prepared by standard methods. Microsatellite markers, obtained from the Marshfield screening set version 6, were amplified as described earlier (29). Genotypes of the previously localized BS locus, which is 17p12 (29), and the chromosomal region of PLOD2, which is 3q23-q24 (30), were assigned.

2 A J. van der Slot, A.-M. Zuurmond, H. E. H. Pruijs, D. O. Sillence, J. DeGroot, T. W. J. Huizinga, and R. A. Bank, submitted for publication.

**Mutation Analysis**—The exon/intron organization of PLOD2 has not been described. PLOD1 and PLOD3, encoding two other members of the lysyl hydroxylase family, both consist of 19 exons (31, 32). The exon/intron boundaries of both genes are identical. Analysis of clones RP11-758H14 and RP11-274H2 showed identical exon/intron boundaries for PLOD2. In addition, PLOD2 shows an extra exon (22), designated exon 13A, which is not found in PLOD1 or PLOD3. To determine DNA sequence variations in exons and exon/intron boundaries of PLOD2, primer pairs were designed to amplify the exons, including the exon/intron boundaries; in addition, a part of the promoter region was amplified (Table I). PCR was carried out on genomic DNA from Bruck syndrome patients, unaffected parents, and a pooled healthy population (Roche Diagnostics) using LA Taq polymerase (Takara Bio, Inc.). PCR consisted of a 3-min interval at 95 °C, 35 cycles of 95 °C for 30 s, 56 °C for 40 s, and 72 °C for 30 s. Data were analyzed using the ABI PRISM® 7500 sequence detection system and consisted of a 5-min interval at 95 °C followed by 40 cycles of 95 °C for 30 s, 56 °C for 40 s, and 72 °C for 30 s. Data were analyzed using Sequence Detector version 1.7.

**PCR Amplification of LH2a and LH2b**—cDNA of human liver tissue, control, and SSc fibroblasts was subjected to LH2a and LH2b PCR amplification. LH2a (145 bp) and LH2b (208 bp) were co-amplified using specific forward (5'-TTAAGGAGAACACTCGGAGACTGA-3') and reverse primers (5'-TAGGACGAGTTGCAGGCTT-3').
GAATACTGA-3') in a total reaction volume of 25 μl containing 1× PCR buffer (Applied Biosystems), 0.4 mM each dNTP, 3.5 mM Mg2+

**Table II**

| Name | Forward primer | Reverse primer |
|------|----------------|----------------|
| LH1  | 5'-CAACGCCTCACCTGACTGTCCTCTC-3' | 5'-CTTCAGGACCGTGACCTTCTT-3' |
| LH2b | 5'-TTAAGGAAGACAGACACCTGCAGAGATGA-3' | 5'-AAATTTTCCCGAGATGCGAGCTTTTTT-3' |
| LH3  | 5'-CTGGGCCCTGAGAGAGGAGGAATG-3' | 5'-TCAGCTTGATCTACTGCCAAAAC-3' |
| COLIA2| 5'-GTCGCCTGACTACACTACCC-3' | 5'-AGCACAGACCGTGATACTACCC-3' |
| B2M  | 5'-TCTCTGATACATGAAATCCTGACCCCTACGTA-3' | 5'-ATCCAAAATGCGCATCTTCACAACCTC-3' |

**Table III**

| Name | Sequence |
|------|----------|
| LH1  | 5'-FAM-cgtgcCTAGGGAGAACGACTGGAATGAGGgcacg-DABCYL-3' |
| LH2b | 5'-FAM-cgtgcCTAGGGAGAACGACTGGAATGAGGgcacg-DABCYL-3' |
| LH3  | 5'-FAM-cgtgcTGTGACCTGGTAGAGGGAATGAGGgcacg-DABCYL-3' |
| LOX  | 5'-FAM-cgtgcCCTGAGCCAGCCACGAGAGGgcacg-DABCYL-3' |
| COLIA2| 5'-FAM-cgtgcCCTGAGCCAGCCACGAGAGGgcacg-DABCYL-3' |
| B2M  | 5'-HEX-cgtgcCTGCCGCTTGAGACATGACTTTGgcacg-DABCYL-3' |

**The Role of PLOD2 in Fibrosis**

**RESULTS**

**Linkage Analysis of BS Families**—To decipher the gene encoding TLH, the gene defect in BS patients was examined. In a previous paper we mapped the BS locus on an 18-centimorgan region on chromosome 17p12 (29). At that time, only a single family was available for genotyping because of the extreme rarity of the disease. To refine the candidate region, two other diagnosed BS families (family DR and family PM) were now screened for linkage to chromosome 17p12. Surprisingly, genotyping analysis excluded the linkage of both families to chromosome 17p12. This implies that, in addition to a BS locus on chromosome 17p12, a BS locus on another chromosomal region exists.

We reasoned that the candidate region for the second BS locus is chromosome 3q23-q24, as PLOD2 encoding LH2 is located in that region (30). This assumption was based on the observation of a parallel increase of LH2 expression and hydroxylysylsine-derived cross-links in osteogenic progenitor cells during the course of in vitro differentiation (35), which suggests that LH2 catalyzes the conversion of the telopeptide lysine residue into hydroxylysine. Indeed, haplotype analysis of family DR and family PM revealed that both families confirm the candidate status of chromosome 3q23 (Fig. 1, a and b).

**Mutation Analysis of BS Families**—To verify that the BS phenotype in the patients in family DR and family PM is indeed due to mutations in PLOD2, a mutation analysis was performed. In both patients of family DR a homozygous missense mutation in exon 17 of C→T was found, resulting in a Thr→Ile substitution at position 608 and 629 (LH2a and LH2b, respectively). Both parents and the healthy sister were carriers of the mutation (Fig. 2a). In the same exon a homozygous missense mutation of G→T was observed in both patients of family PM, resulting in a Gly→Val substitution at positions 601 and 622 (LH2a and LH2b, respectively). The parents were heterozygous for the mutation (Fig. 2b). Neither mutation was detected in a pool of 250 chromosomes of healthy individuals, thereby excluding the possibility that these mutations represent polymorphisms. Mutation analysis of patients from the BS family (family FH) showing linkage to chromosome 17p12 (29) did not reveal any mutations in the exons, exon/intron boundaries, and the promoter region of PLOD2.

**TLH Expression in SSc Fibroblasts**—Because BS indicates that the specific substrate of LH2 is the lysine residue within the collagen telopeptides, we were interested in finding out whether the expression of LH2 is increased in cells present in fibrotic lesions, as the collagen deposited in fibrotic lesions shows an increased hydroxylation of the telopeptides. Real-time PCR analysis of mRNA extracted from SSc skin fibroblasts revealed that the expression of LH2b mRNA was highly increased in these fibroblasts compared with controls (Fig. 3a; controls 0.02 ± 0.01; SSc patients 0.15 ± 0.06; p = 0.003). Interestingly, LH1 (Fig. 3b; controls 0.61 ± 0.23; SSc patients 1.08 ± 0.82) and LH3 (Fig. 3c; controls 0.05 ± 0.02; SSc patients 0.09 ± 0.07) expression levels were unchanged. Expression of LH2a mRNA was undetectable both in controls and SSc patients (Fig. 3d). In agreement with previous data (36, 37), elevated levels of COLIA2 mRNA were found in SSc fibroblasts (Fig. 3e; controls 3.98 ± 2.01; SSc patients 16.53 ± 7.17; p = 0.007). No changes in the expression of LOX mRNA (Fig. 3f; controls 0.43 ± 0.31; SSc patients 0.49 ± 0.24) were observed. Finally, elevated levels of LH2b mRNA expression relative to COLIA2 mRNA expression were found in SSc fibroblasts (controls 0.0057 ± 0.0034; SSc patients 0.0098 ± 0.0021; p = 0.009), whereas LH1 (controls 0.18 ± 0.088; SSc patients 0.06 ± 0.04; p = 0.002), LH3 (controls 0.015 ± 0.007; SSc patients 0.005 ± 0.004; p = 0.002), and LOX (controls 0.12 ± 0.08; SSc patients 0.03 ± 0.005; p = 0.004) mRNA expressions relative to COLIA2 expression were decreased.

Analysis of the collagen, deposited by fibroblasts cultured from fibrotic skin of SSc patients, showed an increase in hydroxylysylsine-derived cross-links, indicating that the hydroxylation of the collagen telopeptides is also increased in the fibrotic skin of SSc patients (Fig. 4; controls 0.041 ± 0.017; SSc...
This is in line with previous in vivo data (38).

DISCUSSION

Fibrosis is characterized by an excessive accumulation of collagen. Furthermore, a change in the collagen cross-link chemistry is found in fibrotic lesions. Therapies to reduce collagen accumulation in fibrosis are mostly focused on the reduction of collagen synthesis and the induction of proteinase activity. A drawback of these approaches is that not only the pathological but also the physiological collagen production and degradation in the surrounding tissue are affected. Recently, it has been postulated that the change in cross-linking, giving a decrease in the proportion of allysine-derived cross-links in favor of hydroxyallysine-derived cross-links, is a unique process in fibrosis (8–15). The amount of hydroxyallysine-derived cross-links (such as pyridinolines) is related to the irreversible accumulation of collagen in fibrotic tissues (10–12, 14, 15). This suggests that collagen containing hydroxyallysine-derived cross-links is more difficult to degrade and therefore contributes significantly to the accumulation of collagen. The increased amount of pyridinolines in fibrosis is the consequence of an overhydroxylation of the lysine residues within the telopeptides. Although the existence of a TLH has been postulated (24, 29), the gene encoding TLH has, to date, not been identified.

Biochemical analysis of the bone of BS patients revealed that the BS phenotype is due to the decreased activity of TLH (29). Three lysyl hydroxylases are known, i.e. LH1, LH2, and LH3, encoded by PLOD1, PLOD2, and PLOD3, respectively. LH1 is a helical lysyl hydroxylase (23, 24), whereas the substrate specificity of LH2 and LH3 is unknown. Here we show, by means of mutation analysis, two different missense mutations in exon 17 of PLOD2 in BS patients, indicating that LH2 is the putative TLH. These mutations are situated in an amino acid sequence showing high homology between the different lysyl hydroxylases, LH1, LH2, and LH3, and between the lysyl hydroxylases of species ranging from Homo sapiens to Caenorhabditis elegans (Fig. 5). Such a strict conservation implies that this region is important for the function of the lysyl hydroxylases in general and that of LH2 in particular.

Mutation analysis of patients from a BS family showing linkage to chromosome 17p12 (29) did not reveal any mutations in the exons, exon/intron-boundaries, or the promoter region of PLOD2. This suggests that these patients must have another defect. Patients linked to chromosome 17 should be called Bruck syndrome type I, whereas patients showing mutations in PLOD2 belong to the Bruck syndrome type II. This subdivision is solely based on genetic data, as we are not aware of phenotypic differences.

BS provides, for the first time, insight into the substrate
specificity of LH2; it is a telopeptide lysyl hydroxylase. As the increased amount of pyridinolines in fibrosis is likely to be the results of increased TLH activity, we investigated the expression of LH2 in fibrotic tissues. Analysis of LH1, LH2a, LH2b, and LH3 mRNA expression in fibrotic skin of SSc patients revealed that, of the collagen-modifying enzymes, only the mRNA level of LH2b relative to COL1A2 was increased. LH2a was undetectable in both control and SSc fibroblasts, indicating that this splice variant is absent in skin fibroblasts and therefore plays no role in fibrosis. Furthermore, we found normal mRNA levels of LOX, which is the enzyme catalyzing the formation of allysine and hydroxyallysine, a step necessary for the formation of cross-links. The increase in pyridinoline cross-links as found in our fibroblast cultures of SSc patients is therefore not due to increased aldehyde formation. Together, these results imply that only LH2b can be responsible for the overhydroxylation of collagen telopeptide lysine residues in SSc skin, leading to the increased formation of pyridinolines. It is therefore reasonable to assume that LH2b plays an important role in the irreversible accumulation of collagen in fibrosis.

The type of cross-links provides a mechanism for regulating the rate of collagen catabolism (10–12, 14, 15). The inhibition of the formation of hydroxyallysine-derived cross-links by specifically inhibiting TLH in order to favor the formation of allysine-derived cross-links is likely to make the collagen more susceptible to proteolytic degradation, leading to a decrease in collagen accumulation. An additional advantage of this approach is that the collagen synthesis needed for normal remodeling of the tissue is not compromised, as TLH up-regulation is specifically seen in fibrosis. Inhibition of LH2 is therefore an attractive way to interfere with fibrotic processes, making LH2 a new and promising target for anti-fibrotic therapies.

Acknowledgment—We thank Dirk-Jan van den Berg for technical assistance.

REFERENCES
1. von der Mark, K. (1999) in Dynamics of Bone and Cartilage (Seibel, M. J., Robins, S. P., and Bilezikian, J. P., eds) pp. 3–30, Academic Press, London
2. Robins, S. P. (1999) in Dynamics of Bone and Cartilage (Seibel, M. J., Robins, S. P., and Bilezikian, J. P., eds) pp. 31–42, Academic Press, London
3. Eyre, D. R., Paz, M. A., and Gallop, P. M. (1994) Annu. Rev. Biochem. 53, 717–748
4. Herbage, D., Le Lous, M., Cohen-Solal, L., and Bazin, S. (1984) Annu. Rev. Biochem. 53, 717–748
5. Robins, S. P. (1982) Methods Biochem. Anal. 28, 329–379
6. Eyre, D. R., Koob, T. J., and Van Ness, K. P. (1984) Anal. Biochem. 137, 380–388
7. Brinckmann, J., Notbohm, H., Trenner, M., Acl, Y., Fietzek, P. P., Schmeller, W., Muller, P. K., and Batge, B. (1999) J. Invest. Dermatol. 113, 617–621
8. Brinckmann, J., Neese, C. M., Gaber, Y., Sohbi, H., Notbohm, H., Hunzelmann, N., Fietzek, P. P., Muller, P. K., Rusti, J., Gebker, R., and Schratter-Kochanek, K. (2001) J. Invest. Dermatol. 117, 269–273
9. Last, J. A., King, T. E., Nerlich, A. G., and Reiser, K. M. (1990) Annu. Rev. Respir. Dis. 141, 307–313
10. Ricard-Blum, S., Bresson-Hadni, S., Vuittot, D. A., Ville, G., and Grimaud, J. A. (1992) Hepatology 15, 599–602
The Role of PLOD2 in Fibrosis

12. Ricard-Blum, S., Esterre, P., and Grimaud, J. A. (1993) *Cell. Mol. Biol.* **39**, 723–727
13. Uzawa, K., Marshall, M. K., Katz, E. P., Tanzawa, H., Yeowell, H. N., and Yamauchi, M. (1998) *Biochim. Biophys. Res. Commun.* **249**, 652–655
14. Bailey, A. J., Baxin, S., Sims, T. J., Le Louis, M., Nicoletis, C., and Delaunay, A. (1975) *Biochim. Biophys. Acta* **405**, 412–421
15. Bailey, A. J., and Light, N. D. (1985) *CIBA Found. Symp.* **114**, 80–96
16. Hautala, T., Byers, M. G., Eddy, R. L., Shows, T. B., Kivirikko, K. I., and Myllyla, R. (1992) *Genomics* **13**, 62–69
17. Heikkinen, J., Toppinen, T., Yeowell, H., Krieg, T., Steinmann, B., Kivirikko, K. I., and Myllyla, R. (1997) *Am. J. Hum. Genet.* **60**, 48–56
18. Yeowell, H. N., and Walker, L. C. (1997) *Proc. Assoc. Am. Physicians* **109**, 383–396
19. Passoja, K., Rautavauma, K., Ala-Kokko, L., Kosonen, T., and Kivirikko, K. I. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 10482–10486
20. Valtavaara, M., Papponen, H., Pirttila, A. M., Hiltunen, K., Helander, H., and Myllyla, R. (1997) *J. Biol. Chem.* **272**, 6631–6634
21. Valtavaara, M., Szpirer, C., Szpirer, J., and Myllyla, R. (1998) *J. Biol. Chem.* **273**, 12881–12886
22. Yeowell, H. N., and Walker, L. C. (1999) *Matrix Biol.* **18**, 179–187
23. Yeowell, H. N., and Walker, L. C. (2000) *Mol. Genet. Metab.* **71**, 212–224
24. Steinmann, B., Eyre, D. R., and Shao, P. (1995) *Am. J. Hum. Genet.* **57**, 1505–1508
25. Brenner, R. E., Vetter, U., Stoss, H., Muller, P. K., and Teller, W. M. (1993) *Eur. J. Pediatr.* **152**, 505–508
26. Breslau-Siderius, E. J., Engelbert, R. H., Pals, G., and van der Sluijs, J. A. (1998) *J. Pediatr. Orthop. B* **7**, 35–38
27. LeRoy, J. G., Nuytinck, L., De Paepe, A., De Rammelaere, M., Gillerot, Y., Verloes, A., Loeyts, B., and De Groote, W. (1998) *Pediatr. Radiol.* **28**, 781–789
28. McPherson, E., and Clemens, M. (1997) *Am. J. Med. Genet.* **70**, 28–31
29. Bank, R. A., Robins, S. P., Wijmenga, C., Breslau-Siderius, L. J., Bardoe, A. F., Van Der Sluijs, H. A., Pruijs, H. E., and Tekoppele, J. M. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 1054–1058
30. Szpirer, C., Szpirer, J., Riviere, M., Vanvooren, P., Valtavaara, M., and Myllyla, R. (1997) *Mamm. Genome.* **8**, 707–708
31. Heikkinen, J., Hautala, T., Kivirikko, K. I., and Myllyla, R. (1994) *Genomics* **24**, 464–471
32. Rautavauma, K., Passoja, K., Helaakoski, T., and Kivirikko, K. I. (2000) *Matrix Biol.* **19**, 73–79
33. Bank, R. A., Beekman, B., Verzijl, N., De Roos, J. A., Sakkee, A. N., and Tekoppele, J. M. (1997) *J. Chromatogr. B Biomed. Sci. Appl.* **703**, 37–44
34. Robins, S. P., Duncan, A., Wilson, N., and Evans, B. J. (1996) *Clin. Chem.* **42**, 1621–1626
35. Uzawa, K., Grzesik, W. J., Nishiura, T., Kaznetsov, S. A., Robey, P. G., Brenner, D. A., and Yamauchi, M. (1999) *J. Bone Miner. Res.* **14**, 1272–1280
36. LeRoy, E. C. (1974) *J. Clin. Invest.* **54**, 880–889
37. Peltonen, L., Palotie, A., Myllyla, R., Krieg, T., and Oikarinen, A. (1985) *J. Invest. Dermatol.* **84**, 14–18
38. Istok, R., Bely, M., Stancikova, M., and Rovensky, J. (2001) *Clin. Exp. Dermatol.* **26**, 545–547